Incyte Germany

Incyte Germany is owned by Incyte.

Incyte is one of the...

• Fortune 500 (#832);
• Russell 3000;
• S&P 500.

Incyte is a company listed under the stock ticker INCY (US).

Incyte has a direct presence in 3 countries.

They are in:

• Biotechnology67%
• Pharmaceuticals33%

View the org chart displaying its 2 main executives

Most searched biographies at Incyte Germany

• Peter Mutzenbecher, Managing Director
• Christof Hilf, Director, Market Access

Create your alert
to follow the executive moves at Incyte Germany.

Incyte has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Incyte Germany

Social media about Incyte Germany

• Incyte Germany on Wikipedia, Google News & Yahoo Finance
• Incyte Germany on LinkedIn, Twitter & YouTube

Contact by email its executives including Peter Mutzenbecher

Call Incyte Germany at +49 692...

View the org chart

Register to receive your alert

Report an error